It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

The UChicago Medicine team will be led by Odunsi as co-principal investigator and includes Christopher Weber, Savas Tay, and ...

Ongoing Monitoring and Follow-Up The prognosis (predicted outcome) for ischemic cardiomyopathy depends on how severely ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

HCM is a relatively common genetic cardiomyopathy that can be a challenge to diagnose, with about one in three patients misdiagnosed as having another cardiomyopathy. Genetic testing identifies a ...

A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.